The Multiple Myeloma Research Foundation (MMRF), a leader in precision medicine, has announced that its founder Kathy Giusti has been appointed Faculty Co-Chair of the Kraft Precision Medicine Accelerator at Harvard Business School (HBS).
Ms. Giusti will lead the Harvard Business School Kraft Precision Medicine Accelerator with HBS faculty member and Co-Chair Richard G. Hamermesh under the umbrella of the School’s Health Care Initiative. She will continue to act as a member of the MMRF Board of Directors and take an active role in the organization’s leadership.
Richard G. Hamermesh
“Precision medicine has the potential to revolutionize the way we prevent, diagnose, treat, and, ultimately, cure cancer and other devastating diseases. I look forward just as much to sharing the MMRF model as I do to learning best practices from other world-class organizations focused on this promising approach,” said Ms. Giusti, who is also a multiple myeloma patient.
The mission of the HBS/Kraft Precision Medicine Accelerator is to speed innovation and medical breakthroughs in precision medicine, the process by which genomic information and other unique characteristics of a person’s disease are used to predict which treatments will be most effective. The Accelerator will convene best-in-class leaders from the business, medical, scientific, and technologic communities to identify and solve challenges slowing the advancement of precision medicine; disseminate best practices and models to overcome these challenges; and, ultimately, enable the faster commercialization of high-impact innovations.
The Accelerator is a partnership between Harvard Business School, The Robert and Myra Kraft Family Foundation, and the Broad Institute. It was established with a $20 million endowment from the Kraft Foundation.
For more information, visit hbs.edu/healthcare/faculty/Pages/kraft-accelerator.aspx. ■